Erenumab

依瑞奈尤单抗

Report date: 2023/10/19 17:18:42
First In Class

Base Information

Drug NameErenumab
Drug Alias Nameerenumabum厄瑞努单抗Erenumab-aooeAimovig安默唯 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCalcitonin gene-related peptide receptor antagonists
TargetsCalcitonin gene-related peptide receptor
Therapy Area/IndicationsHeadacheHot FlashesRosacea +[14] 
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaMigraine Disorders
Original Approved Country/TerritoryUnited States
Original Approved Date2018/05/17
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesCharite University, Berlin, GermanyNovartis Pharma AgIndiana University +[8] 
Inactive CompaniesUniversity Of Maryland, Baltimore
Active IndicationsPost-Traumatic HeadacheCluster HeadacheTrigeminal Autonomic Cephalalgias +[7] 
Inactive IndicationsHeadacheHot FlashesRosacea +[7] 

Other Information

ATC CodeN02CD01
Related LinksWikipediaDrugBankKEGG